Levosef-OZ Tablet is a combination antibiotic formulation containing Levofloxacin 250 mg and Ornidazole 500 mg, designed for the treatment of a broad spectrum of bacterial and protozoal infections. Levofloxacin, a fluoroquinolone antibiotic, exerts its bactericidal effect by inhibiting bacterial DNA gyrase and topoisomerase IV, leading to disruption of DNA replication and cell death. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by causing DNA strand breakage and inhibiting nucleic acid synthesis. This dual-action tablet is indicated for mixed infections involving aerobic and anaerobic organisms, including respiratory tract infections, urinary tract infections, gastrointestinal infections such as amoebiasis and giardiasis, and certain gynecological infections. Levosef-OZ offers enhanced antimicrobial coverage, making it suitable for complicated infections where polymicrobial etiology is suspected. The medication should be used under medical supervision, with dosage adjustments based on infection severity, renal function, and patient response. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and hypersensitivity reactions. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and it is contraindicated in pregnancy and lactation. Appropriate use of Levosef-OZ Tablet contributes to effective infection management and improved clinical outcomes.